Brief: Sanofi Says Dupixent Was Recommended For EU Approval To Treat CSU In Children
27/02/2026 12:05
Feb 27 (Reuters) - Sanofi SA SASY.PA: DUPIXENT RECOMMENDED FOR EU APPROVAL TO TREAT CSU IN CHILDREN DUPIXENT COULD BE FIRST TARGETED MEDICINE FOR CSU IN EU CHILDREN FINAL DECISION IS EXPECTED IN THE COMING MONTHS Source text: ID:nGNE1r5wPH Further company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes